Posts filed under: Pharmaceuticals

Overall, the U.S. immunology drug market is projected to exceed an estimated $38 billion by 2023 due to the entry of new biosimilars and JAK inhibitors into the market....
Continue Reading →
EADV is a non-profit association whose mission is to advance excellence in clinical care, research, education and training in the fields of Dermatology and Venereology....
Continue Reading →
Biosimilars are, as the name would suggest, highly similar and are a more affordable alternative to biologics that is poised to influence the current dynamics of the immunology market. ...
Continue Reading →
The U.S. immunology drug market is expected to grow to $68 billion by 2023 due to the entry of new biosimilars and JAK inhibitors....
Continue Reading →
Sandoz believes the comprehensive data package submitted to the FDA for review confirms that our biosimilar rituximab matches the reference medicine in terms of safety, efficacy and quality...
Continue Reading →
Agreements Provide Non-Exclusive License to Amgen for HUMIRA-Related Intellectual Property in the U.S. Effective Jan. 31, 2023, And in Other Markets on Different Dates...
Continue Reading →
The new drug, Imraldi, marks the third European Commission approval for “biosimilar” versions from the joint venture, Samsung Bioepis, of drugs in a class known as TNF inhibitors....
Continue Reading →
  • Gene Theraphy Device
CAR T-cell therapy approved to treat certain children and young adults with B-cell acute lymphoblastic leukemia - Oncodesign is expanding its service offering in immunology and infectious diseases...
Continue Reading →
Sandoz, a Novartis division, recently announced that The Canadian Drug Expert Committee (CDEC) as part of the Common Drug Review (CDR) process has issued a positive drug reimbursement recommendation for Erelzi (etanercept). Health Canada granted Erelzi a Notice of Compliance...
Continue Reading →
This week the U.S. Food and Drug Administration (FDA) approved a new drug to treat postmenopausal women with advanced breast cancer who have not already taken other drugs....
Continue Reading →

Thank you!

CLOSE

Login

Sign Up

Already have an account? Sign in

×